Cite
HARVARD Citation
Rini, B. et al. (n.d.). LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Annals of oncology. p. . [Online].